Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.34200
Abstract: Key Points Question What is the comparative effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) antagonists for older patients with inflammatory bowel diseases (IBDs)? Findings In a comparative effectiveness study of 754 older… read more here.
Keywords: necrosis factor; safety; vedolizumab tumor; tumor necrosis ... See more keywords